Semaglutide’s altered life in circulation
A borrowed gut hormone acquires an attachment to a blood protein. That small piece of chemistry changes the timescale of the signal.
Albumin binding
Semaglutide is a 31-amino-acid analogue of human GLP-1. Its resemblance to the original is close, with approximately 94% sequence homology. Yet the differences do consequential work. A substitution at position 8 resists DPP-4, the enzyme that breaks down GLP-1. A fatty-acid side chain attached at position 26 binds albumin and slows clearance from blood. The pharmacology discussed in the safety review helps explain how a fleeting gut signal became a long-acting medicine.
I enjoy the thrift of this arrangement. The blood already contains a useful carrier; the molecule acquires a way to travel with it. There is invention here, and also a great deal inherited from the body.
Appetite, gastric emptying and insulin
GLP-1 receptor activation helps the pancreas release insulin in response to glucose, suppresses inappropriate glucagon release and slows gastric emptying. Appetite effects involve brain circuits, including the hypothalamus. The original gut hormone thus supplies a starting point for effects in several places.
The STEP 1 weight-management trial enrolled adults with overweight or obesity without diabetes. It gives the appetite story an outcome that can be measured. Calling it a simple fullness switch understates the medicine, I think: the gastrointestinal adverse-effect record includes nausea, vomiting, diarrhea and constipation, which can make continued treatment difficult.
Clinical results in different populations
The populations deserve to remain attached to these results. Each trial asked its own question.
| Trial and participants | Reported result |
|---|---|
| STEP 1: 1,961 adults with overweight or obesity without diabetes | Mean body-weight change at 68 weeks: −14.9% with semaglutide versus −2.4% with placebo. |
| SELECT: 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes | Cardiovascular death, nonfatal myocardial infarction or nonfatal stroke: HR 0.80; 95% CI 0.72–0.90; P<0.001. |
| FLOW: 3,533 people with type 2 diabetes and chronic kidney disease | Major kidney-disease events: HR 0.76; 95% CI 0.66–0.88. |
| SURMOUNT-5: 751 adults with obesity | At 72 weeks, mean weight change was −20.2% with tirzepatide versus −13.7% with semaglutide; P<0.001. |
The cardiovascular result impresses me especially: an altered appetite hormone was tested against serious clinical events. The comparison with tirzepatide answers a weight question in another trial; it cannot supply a single ranking across all these outcomes.
Documented risks
The dedicated semaglutide safety review describes mainly transient gastrointestinal adverse effects and an increased risk of biliary disease, including gallstones. Acute pancreatitis is a class warning. Diabetic-retinopathy complications were a concern in people with pre-existing retinopathy undergoing rapid glucose correction.
The thyroid C-cell tumour warning arose from rodent findings. A personal or family history of medullary thyroid carcinoma or MEN-2 is a contraindication; the human cancer signal remains unconfirmed. Pancreatic and thyroid-cancer risks also remain difficult to settle because the events are uncommon. The review’s favourable overall benefit-risk assessment in type 2 diabetes carries those cautions with it.
Semaglutide has FDA-approved uses across type 2 diabetes, chronic weight management, cardiovascular risk reduction in the specified population and MASH, approved in 2025. An indication describes a particular use of a regulated medicine. I trust an approval only within its named indication and product.
Accounts of quieter food thoughts
People often describe less preoccupation with food, fewer cravings and earlier fullness. Others describe sulfur-smelling burps, reflux, bowel changes or fatigue. These are anecdotal accounts rather than clinical evidence; they cannot establish how often an effect occurs or which mechanism caused it.
The phrase “food noise” conveys something the weight result alone misses about how people describe appetite. I believe those descriptions deserve attention; an unverified report still cannot borrow the confidence of a controlled trial. Accounts of reduced interest in alcohol are exploratory, too; they establish no approved use for that purpose.
Compounded preparations
The shortage-based exceptions have ended. Patient-specific compounding under section 503A must still satisfy FDA’s ordinary conditions, including restrictions on copies. FDA has documented dosing errors and adverse events requiring hospitalization involving compounded semaglutide.
Those facts concern the preparation and its legal route as well as the molecule. The trial results above cannot certify the identity, concentration or quality of a different preparation.